1-5 of 5
Michael Dickinson
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Correction: ATF3 Repression of BCL-XL Determines Apoptotic Sensitivity to HDAC Inhibitors Across Tumor Types

Free
Anderly C. Chüeh, Janson W.T. Tse, Michael Dickinson, Paul Ioannidis, Laura Jenkins, Lars Togel, BeeShin Tan, Ian Luk, Mercedes Davalos-Salas, Rebecca Nightingale, Matthew R. Thompson, Bryan R.G. Williams, Guillaume Lessene, Erinna F. Lee, Walter D. Fairlie, Amardeep S. Dhillon, John M. Mariadason
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (18): 3826.
https://doi.org/10.1158/1078-0432.CCR-23-2100
Published: 15 September 2023
View articletitled, Correction: ATF3 Repression of BCL-XL Determines Apoptotic Sensitivity to HDAC Inhibitors Across Tumor Types
Open the PDF for Correction: ATF3 Repression of BCL-XL Determines Apoptotic Sensitivity to HDAC Inhibitors Across Tumor Types in another window
Journal Articles

Safety and Efficacy of Axicabtagene Ciloleucel versus Standard of Care in Patients 65 Years of Age or Older with Relapsed/Refractory Large B-Cell Lymphoma

Open Access
Jason R. Westin, Frederick L. Locke, Michael Dickinson, Armin Ghobadi, Mahmoud Elsawy, Tom van Meerten, David B. Miklos, Matthew L. Ulrickson, Miguel-Angel Perales, Umar Farooq, Luciano Wannesson, Lori Leslie, Marie José Kersten, Caron A. Jacobson, John M. Pagel, Gerald Wulf, Patrick Johnston, Aaron P. Rapoport, Linqiu Du, Saran Vardhanabhuti, Simone Filosto, Jina Shah, Julia T. Snider, Paul Cheng, Christina To, Olalekan O. Oluwole, Anna Sureda
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (10): 1894–1905.
https://doi.org/10.1158/1078-0432.CCR-22-3136
Published: 15 May 2023
View articletitled, Safety and Efficacy of Axicabtagene Ciloleucel versus Standard of Care in Patients 65 Years of Age or Older with Relapsed/Refractory Large B-Cell Lymphoma
Open the PDF for Safety and Efficacy of Axicabtagene Ciloleucel versus Standard of Care in Patients 65 Years of Age or Older with Relapsed/Refractory Large B-Cell Lymphoma in another window
Includes: Supplementary data
Journal Articles

A Phase I/II Open-Label Study of Molibresib for the Treatment of Relapsed/Refractory Hematologic Malignancies

Open Access
Mark A. Dawson, Gautam Borthakur, Brian J.P. Huntly, Anastasios Karadimitris, Adrian Alegre, Aristeidis Chaidos, Dan T. Vogl, Daniel A. Pollyea, Faith E. Davies, Gareth J. Morgan, Jacob L. Glass, Manali Kamdar, Maria-Victoria Mateos, Natalia Tovar, Paul Yeh, Regina García Delgado, Faisal Basheer, Ludovica Marando, Paolo Gallipoli, Anastasia Wyce, Anu Shilpa Krishnatry, Olena Barbash, Evi Bakirtzi, Geraldine Ferron-Brady, Natalie O. Karpinich, Michael T. McCabe, Shawn W. Foley, Thierry Horner, Arindam Dhar, Brandon E. Kremer, Michael Dickinson
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (4): 711–722.
https://doi.org/10.1158/1078-0432.CCR-22-1284
Published: 16 February 2023
View articletitled, A Phase I/II Open-Label Study of Molibresib for the Treatment of Relapsed/Refractory Hematologic Malignancies
Open the PDF for A Phase I/II Open-Label Study of Molibresib for the Treatment of Relapsed/Refractory Hematologic Malignancies in another window
Includes: Supplementary data
Journal Articles

ATF3 Repression of BCL-XL Determines Apoptotic Sensitivity to HDAC Inhibitors across Tumor Types

Free
Anderly C. Chüeh, Janson W.T. Tse, Michael Dickinson, Paul Ioannidis, Laura Jenkins, Lars Togel, BeeShin Tan, Ian Luk, Mercedes Davalos-Salas, Rebecca Nightingale, Matthew R. Thompson, Bryan R.G. Williams, Guillaume Lessene, Erinna F. Lee, Walter D. Fairlie, Amardeep S. Dhillon, John M. Mariadason
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (18): 5573–5584.
https://doi.org/10.1158/1078-0432.CCR-17-0466
Published: 15 September 2017
View articletitled, ATF3 Repression of BCL-XL Determines Apoptotic Sensitivity to HDAC Inhibitors across Tumor Types
Open the PDF for ATF3 Repression of BCL-XL Determines Apoptotic Sensitivity to HDAC Inhibitors across Tumor Types in another window
Includes: Supplementary data
Journal Articles

Romidepsin for Cutaneous T-cell Lymphoma

Free
H. Miles Prince, Michael Dickinson
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (13): 3509–3515.
https://doi.org/10.1158/1078-0432.CCR-11-3144
Published: 01 July 2012
View articletitled, Romidepsin for Cutaneous T-cell Lymphoma
Open the PDF for Romidepsin for Cutaneous T-cell Lymphoma in another window